Phase 3 N=371 Randomized Quadruple-blind Treatment

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

Scalp Psoriasis

Bottom Line

View on ClinicalTrials.gov: NCT02933866 ↗

Enrolled (actual)

371

Serious AEs

0.0%

Results posted

Dec 2018

Primary outcome: Primary: Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success — 49; 41 Participants — p=0.2961

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: DSXS topical (Drug); Vehicle topical (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Sun Pharmaceutical Industries, Inc.
Primary completion: Nov 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success	49; 41	0.2961

Summary

A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS topical product in Patients with Mild to Severe Scalp Psoriasis

Eligibility Criteria

Inclusion Criteria

Male or non-pregnant, non-lactating females 18 years of age and older.

Exclusion Criteria

Females who are pregnant, lactating or likely to become pregnant during the study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02933866). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.